# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY DEVICE ONLY TEMPLATE

A. 510(k) Number k060351   
B. Purpose for Submission: New device   
C. Measurand: Oxycodone   
D. Type of Test: Qualitative immunoassay, lateral flow immunochromatographic   
E. Applicant: MedTox Diagnostics   
F. Proprietary and Established Names: MedTox Oxycodone

# G. Regulatory Information:

1. Regulation section: 21 CFR 862.3650, Enzyme Immunoassay, Opiates   
2. Classification: Class II   
3. Product Code: DJG   
4. Panel: Toxicology (91)

# H. Intended Use:

1. Intended use(s): Refer to Indications for use below.

2. Indication(s) for use: The MEDTOX OXYCODONE Test System uses immunochromatographic® test strips for the rapid, qualitative detection of oxycodone in human urine. It is intended for prescription use.

The test detects oxycodone at concentrations of $1 0 0 ~ \mathrm { { n g / m L } }$ and above.

The MEDTOX® OXYCODONE assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result.

3. Special condition for use statement(s):

The MEDTOX OXYCODONE provides only a preliminary analytical test ® result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result.

The assay is intended for prescription use in point-of-care settings.

Tests for oxycodone cannot distinguish between abused drugs and certain prescribed medications.

Certain foods or medications may interfere with tests for oxycodone and cause false positive results.

# 4. Special instrument Requirements:

Not applicable. The device is a visually read single-use device.

# I. Device Description:

The product is a single-use device in a cassette format. The device includes the immunochromatographic strip enclosed in plastic, a plastic dropper for dispensing urine, and the package insert. At one end is the sample well where the urine sample is applied. The test reaction is initiated by movement of the sample through the test strip. In the middle of the device is a read window with a test line for oxycodone and a control line. Above the read window are interpretations for negative or nonnegative for the test line and valid or invalid for the control line.

Description of the test antibody: monoclonal mouse antibody against oxycodone.

Description of the control line antibody: rabbit polyclonal anti-mouse.

# J. Substantial Equivalence Information:

1. Predicate device name(s): DRI Oxycodone Assay   
2. Predicate 510(k) number(s): k040411   
3. Comparison with predicate: Both devices are for the qualitative determination of the same analyte in the same matrix, and utilize the same cutoff concentration. The predicate uses

liquid reagents on automated clinical chemistry analyzers. The candidate device is visually read and designed for single use only.

The reagent formulations vary between the two devices.

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Predicate</td><td rowspan=1 colspan=1>Device</td></tr><tr><td rowspan=1 colspan=1>Cutoff</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>100 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Cross-reactivity toopiates and oxycodonemetabolites other thanoxymorphone</td><td rowspan=1 colspan=1>Less than 1%</td><td rowspan=1 colspan=1>2% or less</td></tr><tr><td rowspan=1 colspan=1>Test Antibodies</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Mouse monoclonal anti-oxycodone</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Predicate</td><td rowspan=1 colspan=1>Device</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Automated homogeneousenzyme immunoassay</td><td rowspan=1 colspan=1>Lateral flowimmunochromatographic</td></tr><tr><td rowspan=1 colspan=1>Procedure</td><td rowspan=1 colspan=1>Automated</td><td rowspan=1 colspan=1>Manual</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Controls must be runseparately in the samemanner as patientsamples</td><td rowspan=1 colspan=1>Control provided on eachstrip</td></tr><tr><td rowspan=1 colspan=1>Calibration Required</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Cross-reactivity tooxymorphone (primarymetabolite)</td><td rowspan=1 colspan=1>103%</td><td rowspan=1 colspan=1>50%</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

The sponsor did not reference any standards in this submission.

# L. Test Principle:

The test employs lateral flow immunochromatographic technology.

Drug in the sample and drug-labeled conjugate (containing a chromagen) compete for antibody binding sites in the test area of the test strip. Binding of drug in the sample causes the absence of a line at the test area, i.e., a positive result. When drug is not present in the sample, the drug-labeled conjugate binds at the test line, resulting in formation of a line, i.e., a negative result. The absence or presence of the line is determined visually by the operator.

The device also has an internal process control which indicates that an adequate volume of sample has been added and that the immunochromatographic strip is intact.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

The sponsor performed two Precision/Reproducibility studies. The first was conducted at the sponsor’s facility.

Specimen description: drug free urine spiked with oxycodone   
Number of days: three   
Replicates per day: two   
Lots of product used: one   
Number of operators: three   
Operator: manufacturer staff   
Testing Facility: manufacturer

Results of the study are presented below:

Oxycodone Precision Study Results at Sponsor’s Facility   

<table><tr><td rowspan=1 colspan=1>Concentration ofsample, ng/mL</td><td rowspan=1 colspan=1>Number ofdeterminations</td><td rowspan=1 colspan=1>Results# Neg/ #Pos</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=1>54/0</td></tr><tr><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=1>54/0</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=1>50/4</td></tr><tr><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=1>14/40</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=1>4/50</td></tr><tr><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=1>1/53</td></tr><tr><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=1>0/54</td></tr></table>

The second precision study was performed at three point of care sites.

Specimen description: drug free urine spiked with oxycodone   
Number of days: one   
Replicates per day: ninety (six concentrations X fifteen replicates   
per concentration)   
Lots of product used: one   
Number of operators: nine   
Operators: POC staff, DOA Collection Center Staff, Rehabilitation   
Center Staff   
Testing Facilities: Three POC sites

Results of the study are presented below:

Oxycodone Precision Study Results at Point of Care Sites   

<table><tr><td rowspan=2 colspan=1>Concentration ofsample,ng/mL</td><td rowspan=1 colspan=3>Number ofdeterminations</td><td rowspan=1 colspan=3>Results# Neg/ #Pos</td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>Site 3</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15/0</td><td rowspan=1 colspan=1>15/0</td><td rowspan=1 colspan=1>15/0</td></tr><tr><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15/0</td><td rowspan=1 colspan=1>15/0</td><td rowspan=1 colspan=1>15/0</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>13/2</td><td rowspan=1 colspan=1>15/0</td><td rowspan=1 colspan=1>14/1</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0/15</td><td rowspan=1 colspan=1>3/12</td><td rowspan=1 colspan=1>3/12</td></tr><tr><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0/15</td><td rowspan=1 colspan=1>2/13</td><td rowspan=1 colspan=1>1/14</td></tr><tr><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0/15</td><td rowspan=1 colspan=1>0/15</td><td rowspan=1 colspan=1>0/15</td></tr></table>

$b$ . Linearity/assay reportable range: Not applicable. The assay is intended for qualitative use.

c. Traceability (controls, calibrators, or method): External control materials are recommended but are not specifically identified in the labeling.

The device has an internal process control. Users are instructed to follow federal, state, and local guidelines when determining when to run external controls.

# d. Detection limit:

Sensitivity of this assay is characterized by validating performance around the claimed cutoff concentration ( $1 0 0 ~ \mathrm { { n g / m L } ) }$ of the assay, including a determination of the lowest concentration of drug that is capable of producing a positive result.

This information appears in the precision section, above.

e. Analytical specificity:

Cross-reactivity was established by spiking various concentrations of similarly structured drug compounds into drug-free urine. By analyzing various concentration of each compound the sponsor determined the concentration of the drug that produced a response approximately equivalent to the cutoff concentration of the assay. Results of those studies appear in the table(s) below:

<table><tr><td rowspan=1 colspan=1>Drug compound</td><td rowspan=1 colspan=1>Responseequivalent tocutoff in ng/mL</td><td rowspan=1 colspan=1>Percent Cross-Reactivity</td></tr><tr><td rowspan=1 colspan=1>6-monoacetylmorphine</td><td rowspan=1 colspan=1>Negative at100,000</td><td rowspan=1 colspan=1>&lt; 1%</td></tr><tr><td rowspan=1 colspan=1>Apomorphine</td><td rowspan=1 colspan=1>Negative at100,000</td><td rowspan=1 colspan=1>&lt; 1%</td></tr></table>

Page 6 of 12   

<table><tr><td rowspan=1 colspan=1>Drug compound</td><td rowspan=1 colspan=1>Responseequivalent tocutoff in ng/mL</td><td rowspan=1 colspan=1>Percent Cross-Reactivity</td></tr><tr><td rowspan=1 colspan=1>Codeine</td><td rowspan=1 colspan=1>5,000</td><td rowspan=1 colspan=1>2%</td></tr><tr><td rowspan=1 colspan=1>Dihydrocodeine</td><td rowspan=1 colspan=1>10,000</td><td rowspan=1 colspan=1>1%</td></tr><tr><td rowspan=1 colspan=1>Ethylmorphine</td><td rowspan=1 colspan=1>5,000</td><td rowspan=1 colspan=1>2%</td></tr><tr><td rowspan=1 colspan=1>Heroin</td><td rowspan=1 colspan=1>Negative at100,000</td><td rowspan=1 colspan=1>&lt; 1%</td></tr><tr><td rowspan=1 colspan=1>Hydrocodone</td><td rowspan=1 colspan=1>75,000</td><td rowspan=1 colspan=1>&lt; 1%</td></tr><tr><td rowspan=1 colspan=1>Hydromorphone</td><td rowspan=1 colspan=1>50,000</td><td rowspan=1 colspan=1>&lt; 1%</td></tr><tr><td rowspan=1 colspan=1>Levorphanol</td><td rowspan=1 colspan=1>Negative at 50,000</td><td rowspan=1 colspan=1>&lt; 1%</td></tr><tr><td rowspan=1 colspan=1>Morphine</td><td rowspan=1 colspan=1>50,000</td><td rowspan=1 colspan=1>&lt; 1%</td></tr><tr><td rowspan=1 colspan=1>Morphine-3-β-glucuronide</td><td rowspan=1 colspan=1>Negative at100,000</td><td rowspan=1 colspan=1>&lt; 1%</td></tr><tr><td rowspan=1 colspan=1>Morphine-6-β-glucuronide</td><td rowspan=1 colspan=1>Negative at100,000</td><td rowspan=1 colspan=1>&lt; 1%</td></tr><tr><td rowspan=1 colspan=1>Nalorphine</td><td rowspan=1 colspan=1>Negative at100,000</td><td rowspan=1 colspan=1>&lt; 1%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Drug compound</td><td rowspan=1 colspan=1>Responseequivalent tocutoff in ng/mL</td><td rowspan=1 colspan=1>Percent Cross-Reactivity</td></tr><tr><td rowspan=1 colspan=1>Naloxone</td><td rowspan=1 colspan=1>50,000</td><td rowspan=1 colspan=1>&lt; 1%</td></tr><tr><td rowspan=1 colspan=1>Naltrexone</td><td rowspan=1 colspan=1>Negative at100,000</td><td rowspan=1 colspan=1>&lt; 1%</td></tr><tr><td rowspan=1 colspan=1>Norcodeine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>&lt; 1%</td></tr><tr><td rowspan=1 colspan=1>Oxymorphone</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>50%</td></tr><tr><td rowspan=1 colspan=1>Thebaine</td><td rowspan=1 colspan=1>Negative at100,000</td><td rowspan=1 colspan=1>&lt; 1%</td></tr></table>

The following compounds were evaluated for potential positive and/or negative interference with the assay. To evaluate for interference the sponsor prepared two control samples that consisted of drug-free urine spiked with $2 5 ~ \mathrm { n g / m L }$ (to test for positive interference) and $1 5 0 ~ \mathrm { { n g / m L } }$ (to test for negative interference) of oxycodone. Next, $1 0 0 ~ \mu \mathrm { g / m L }$ of all of the potentially interfering compounds were added to separate aliquots of the control samples and analyzed. There were no deviations from the expected results for the following compounds:

Acetylsalicylic Acid   
Acetaminophen   
Brompheniramine   
Caffeine   
Carbamazepine   
Chlorpheniramine   
Cocaine   
Doxylamine   
Dextromethorphan   
5,5 Diphenylhydantoin   
Ibuprofen   
Phenobarbital   
d-Pseudoephedrine   
Salicylic Acid

The sponsor did a second interference study which tested for positive interference only. It is noted that these compounds were spiked into drug-free urine (zero concentration oxycodone) only. All of the compounds listed below were spiked in at a concentration of $1 0 0 ~ \mu \mathrm { g / m L }$ with the following exceptions: Alprazolam $@$ $\textcircled { 1 } 2 5 ~ \mu \mathrm { g / m L }$ , Alprazolam, 1-Hydroxy $\textcircled { a } 1 0 ~ \mu \mathrm { g / m L }$ , Buprenorphine $@$ $\textcircled { \mathscr { V } } 1 0 ~ \mu \mathrm { g } / \mathrm { m L }$ , Fentanyl $\textcircled { a } 1 0 ~ \mu \mathrm { g / m L }$ , 11-hydroxy$\Delta ^ { 9 }$ -THC $\textcircled { a } 1 0 ~ \mu \mathrm { g / m L }$ , Lorazepam glucuronide $\textcircled { a } 1 0 ~ \mu \mathrm { g / m L }$ , 11- Nor-9-carboxy $\Delta ^ { 9 }$ -THC $\textcircled { a } 1 0 ~ \mu \mathrm { g / m L }$ , Olanzapine $\textcircled { a } 1 0 ~ \mu \mathrm { g / m L }$ , Oxazepam glucuronide $\textcircled { a } 1 0 ~ \mu \mathrm { g / m L }$ , and Triazolam, 1-hydroxy $@$ $1 0 ~ \mu \mathrm { g / m L }$ . There were no deviations from the expected negative results.

Acecainide   
Acetaminophen   
Acetylsalicylic   
Acid   
Allobarbital   
Alprazolam   
Alprazolam, 1-   
Hydroxy   
p-Aminobenzoic   
Acid   
7-Amino  
clonazepam   
7-Amino  
flunitrazepam   
Aminoglutethimid   
e   
l-Aminopyrine   
Amitriptyline   
Amobarbital   
Amoxapine   
Amoxicillin   
d-Amphetamine   
l-Amphetamine   
Ampicillin   
Aprobarbital   
l-Ascorbic Acid   
Aspartame   
Atenolol   
Atropine Sulfate   
Barbital   
Barbituric Acid   
Benzilic Acid   
Benzoic Acid   
Benzocaine   
Benzoylecgonine   
Benzphetamine   
Benztropine   
Brompheniramine   
Buprenorphine   
Bupropion   
Butabarbital   
Butalbital   
Dextromethorpha   
n   
Diazepam   
Diclofenac   
Diethylpropion   
Diflunisal   
Digoxin   
Dimenhydrinate   
1,3-   
Dimethylbarbitur   
ic acid   
Diphenhydramin   
e   
Domperidone   
Dopamine   
Doxepin   
Doxylamine   
Ecgonine   
Ecgonine Methyl   
Ester   
EDDP   
Efavirenz   
EMDP   
Ephedrine   
Equilin   
Erythromycin   
Estrone   
Ethanol   
Fenfluramine   
Fenoprofen   
Fentanyl   
Flunitrazepam   
Fluoxetine   
Lurazepam   
Furosemide   
Fuvoxamine   
Gentisic Acid   
Glutethimide   
Guaiacol Glyceryl   
Ether

Page 8 of 12

Haloperidol   
Hexobarbital   
Hippuric acid   
Hydralazine   
Hydrochlorothiazi   
de   
Hydrocortisone   
Hydroxybupropion   
Hydroxyhippuric   
acid   
l-11-Hydroxy- $\cdot \Delta ^ { 9 }$ -   
THC   
p  
Hydroxyphenobar   
bital   
4-   
Hydroxyphencycli   
dine   
3-   
Hydroxytyramine   
Hydroxyzine   
Ibuprofen   
Imipramine   
Iproniazid   
(R)-Isoproterenol   
Isoxsuprine   
Ketamine   
Ketoprofen   
Labetalol   
Lidocaine   
Lithium carbonate   
Loperamide   
Lorazepam   
Lorazepam   
glucuronide   
Loxapine   
Lysergic Acid   
Lysergic Acid   
Diethylamide   
Maprotiline   
MDA   
MDEA   
MDMA   
Melanin   
Meperidine   
Mephobarbital   
Mepivacaine   
Mesoridazine   
Methadone   
d  
Methamphetamin   
e   
Methamphetamin   
e   
Methaqualone   
Methcathinone   
Methocarbamol   
Methoxyphenami   
ne   
Methylphenidate   
Methylprylon   
Metoprolol   
Midazolam   
Mirtazapine   
Nalidixic Acid   
Naproxen   
Niacinamide   
Nicotine   
Nifedipine   
Nitrazepam   
Nitrofurantoin   
Norclomipramine   
Nordiazepam   
Nordoxepin   
Norethindrone   
Norlysergic Acid   
Normeperidine   
Norpropoxyphen   
e   
I  
Norpseudoephedr   
ine   
11-Nor-9-   
carboxy- $\cdot \Delta ^ { 9 }$ -THC   
11-Nor-9-   
carboxy- Δ 8 -   
THC   
Nortriptyline   
Noscapine   
Nylidrin   
Octopamine   
Ofloxacin   
Olanzapine   
Omeprazole   
Orphenadrine   
Oxalic Acid   
Oxaprosin   
Oxazepam   
Oxazepam   
glucuronide   
Oxolinic Acid   
Oxymetazoline   
Papaverine   
hydrochloride   
Penicillin G

Pentazocine Pentobarbital

Perphenazine Phenallymal Phenacetin Phencyclidine

Phendimetrazine   
Phenelzine   
Phenethylamine   
Pheniramine   
Phenmetrazine   
Phenobarbital   
Phenothiazine   
Phentermine   
Phentoin   
Phenylbutazone   
Phenylephrine   
Phenylpropanolam   
ine   
Piroxicam   
Prazosin   
Prednisolone   
Prednisone   
Procaine   
Procainamide   
Prochlorperazine   
Promazine   
Promethazine   
Propoxyphene   
Propranolol   
Protriptyline   
d-Pseudoephedrine   
Pyrilamine   
Quetiapine   
Quinidine   
Ranitidine   
Riboflavin   
Rifampin   
Salicylic Acid   
Secobarbital   
Selegiline   
Serotonin   
Sertraline   
Sildenafil   
Sulfamethazine   
Sulindac   
Talbutal   
Temazepam   
Tetracycline   
$\Delta ^ { \mathrm { ~ 9 ~ } }$ -   
Tetrahydrocannabi   
nol   
Δ 8 -   
Tetrahydrocannabi   
nol   
Tetrahydrozoline   
Theophylline   
Thiamine   
Thiopental

Thioridazine Triazolam, 1- Tryptophan Thiothixine hydroxy Tyramine Tolbutamide Trifluoperazine Tyrosine Tolmetin Trimethoprim Valproic Acid Trazodone Trimipramine Venlafaxine Triamterene Tripelennamine Verapamil Triazolam Tryptamine Zomepirac

There is the possibility that other substances and/or factors not listed above may interfere with the test and cause false results, e.g., technical or procedural errors.

To test for potential positive/and or negative interference from endogenous conditions the sponsor performed the following studies:

To assess the effects of $\mathrm { p H }$ on the assay, the sponsor prepared samples from a pH of 4-9 and then to separate aliquots spiked in oxycodone at concentrations of 25 and $1 5 0 ~ \mathrm { { n g / m L } }$ . There were no deviations from the expected results.

The sponsor did a similar study with specific gravity values of 1.003, 1.005, 1.010, 1.015, 1.020, 1.025, 1.030, and 1.035 with urine samples spiked at 25 and $1 5 0 ~ \mathrm { { n g / m L } }$ . There were no deviations from the expected results.

For other endogenous substances, the sponsor performed a study which tested for positive interference only. It is noted that these compounds were spiked into drug-free urine (zero concentration oxycodone) only. The following table lists the compounds, the concentration that was spiked into drug-free urine, and the result.

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>Concentration</td><td rowspan=1 colspan=1>MEDTOXOxycodoneresult</td></tr><tr><td rowspan=1 colspan=1>Acetaldehyde</td><td rowspan=1 colspan=1>100 μg/ml</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>Acetone</td><td rowspan=1 colspan=1>100 μg/ml</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>Albumin, human</td><td rowspan=1 colspan=1>20 mg/ml</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>Bilirubin</td><td rowspan=1 colspan=1>200μg/ml</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>Cholesterol</td><td rowspan=1 colspan=1>100μg/ml</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>Creatinine</td><td rowspan=1 colspan=1>100μg/ml</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>d,1-Thyroxin</td><td rowspan=1 colspan=1>100μg/ml</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>Epinephrine</td><td rowspan=1 colspan=1>100μg/ml</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>B-Estradiol</td><td rowspan=1 colspan=1>100μg/ml</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>Estriol</td><td rowspan=1 colspan=1>100μg/ml</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>Glucose, Standard Solution</td><td rowspan=1 colspan=1>100μg/ml</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin,human</td><td rowspan=1 colspan=1>100μg/ml</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>Sodium Chloride</td><td rowspan=1 colspan=1>100 μg/ml</td><td rowspan=1 colspan=1>NEG</td></tr></table>

Page 10 of 12   

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>Concentration</td><td rowspan=1 colspan=1>MEDTOXOxycodoneresult</td></tr><tr><td rowspan=1 colspan=1>Tetra hydrocortisone</td><td rowspan=1 colspan=1>100μg/ml</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>Uric Acid</td><td rowspan=1 colspan=1>100 μg/ml</td><td rowspan=1 colspan=1>NEG</td></tr></table>

$f .$ Assay cut-off:

The Substance Abuse and Mental Health Services Administration (SAMHSA) has not recommended a cutoff concentration for oxycodone. The sponsor’s claimed cutoff is $1 0 0 ~ \mathrm { { n g / m L } }$ .

Characterization of how the device performs analytically around the claimed cutoff concentration appears in the precision section, above.

# 2. Comparison studies:

a. Method comparison with predicate device: The candidate device was compared both to a reference method, GC/MS, and to the predicate device.

A total of 161 samples (116 negative and 45 positive) were evaluated by the candidate device and by GC/MS and/or the predicate device.

Sample description: Unaltered clinical urine samples were evaluated. 37 additional diluted samples were also included in the study. The samples were prepared by diluting clinical samples with high drug concentrations with drug-free urine. This was done in order to obtain samples near the cutoff concentration of the assay, because the sponsor was not able to obtain unaltered samples near the cutoff.

Sample selection: Samples previously analyzed by the predicate device were selected to be analyzed by the candidate device. Samples were chosen for the study based on whether they screened positive or negative by the predicate device.

Only those samples found positive by the predicate device were analyzed by GC/MS. A portion of samples having drug concentrations that were below the cutoff concentration of the assay were also evaluated by GC/MS.

The study included an adequate number of samples that contained drugs near to the cutoff concentration of the assay. Approximately $10 \%$ of the study samples are evenly distributed between plus and minus $50 \%$ of the claimed cutoff concentration

Number of study sites: three Type of study site(s): POC setting

# Operator description: POC staff, DOA Collection Center Staff, Rehabilitation Center Staff

# Candidate Device Results vs. stratified GC/MS Values

<table><tr><td>Candidate Device Results</td><td>Negative by Immunoassay Predicate Device</td><td>Concentration of up to the cutoff -50%</td><td>Near Cutoff Negative (Between 50% below the cutoff and the cutoff</td><td>Near Cutoff Positive (Between the cutoff and 50% above the cutoff</td><td>High Positive (greater than 50% above the cutoff concentration)</td></tr><tr><td>Positive</td><td>0</td><td>2</td><td>concentration) 2</td><td>concentration) 6</td><td>37</td></tr><tr><td>Negative</td><td>103</td><td>5</td><td>4</td><td>1</td><td>1</td></tr></table>

GC/MS values used to categorize samples in this table are determined by adding together the concentration of oxycodone plus $50 \%$ of the concentration of oxymorphone, based on the sponsor’s cross-reactivity studies.

$\%$ Agreement among positives is $9 6 \%$ $\%$ Agreement among negatives is $9 7 \%$

The sponsor also performed a method comparison study at their own facility using many of the same samples as in the POC study above. Results between the two studies were similar.

b. Matrix comparison: Not applicable. The assay is intended for only one sample matrix.

3. Clinical studies:

a. Clinical sensitivity: Not applicable. Clinical studies are not typically submitted for this device type.   
b. Clinical specificity: Not applicable. Clinical studies are not typically submitted for this device type.   
c. Other clinical supportive data (when a and b are not applicable):

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range: Not applicable.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.